A rare KMT2A::CBL transcript in an acute monoblastic leukemia patient with an unfavorable outcome.
Mol Biol Rep
; 51(1): 561, 2024 Apr 21.
Article
em En
| MEDLINE
| ID: mdl-38643442
ABSTRACT
BACKGROUND:
Lysine [K] methyltransferase 2A (KMT2A, previously known as MLL) gene rearrangements are common in acute leukemias of various lineages and are associated with features such as chemotherapy resistance and rapid relapse. KMT2ACBL is a rare fusion of unknown pathogenesis generated by a unique interstitial deletion of chromosome 11 that has been reported across a wide age range in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients. The leukemogenic effect of the KMT2ACBL rearrangement and its association with clinical prognosis have not been well clarified. METHODS ANDRESULTS:
We report the case of a 64-year-old female who was diagnosed with acute monoblastic leukemia (M5a) and who acquired the rare KMT2ACBL fusion. The patient received multiple cycles of therapy but did not achieve remission and eventually succumbed to severe infection and disease progression. Additionally, we characterized the predicted KMT2A-CBL protein structure in this case to reveal the underlying leukemogenic mechanisms and summarized reported cases of hematological malignancies with KMT2ACBL fusion to investigate the correlation of gene rearrangements with clinical outcomes.CONCLUSIONS:
This report provides novel insights into the leukemogenic potential of the KMT2ACBL rearrangement and the correlation between gene rearrangements and clinical outcomes.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia Monocítica Aguda
/
Histona-Lisina N-Metiltransferase
/
Proteínas Proto-Oncogênicas c-cbl
/
Proteína de Leucina Linfoide-Mieloide
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article